Vicore Pharma’s drug candidate, C21 formulation, currently in a phase 2a trial aimed at people with idiopathic pulmonary fibrosis (IPF), has been patented.
The WHO has delayed its controversial EB 124/14 amendment that would, according to some groups, broaden the organisation’s definition of “counterfeit” from its current focus on patient health to include infringements of intellectual property.
Advances in organic electronics have allowed UK-based Novalia to
develop a proprietary technology for circuit printing on packaging
- using conventional printing equipment - which can be used to
identify when a package has been tampered...
AstraZeneca has started construction a €30 million tablet
manufacturing plant in Egypt that could form a springboard for an
expansion into emerging markets.
The World Health Organisation has set up its Commission on
Intellectual Property Rights, Innovation and Public Health (CIPIH),
charged with working out a way to provide access to medicines in
developing countries without compromising...
